123 related articles for article (PubMed ID: 17845056)
1. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
2. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain.
You M; Li E; Hristova K
Biochemistry; 2006 May; 45(17):5551-6. PubMed ID: 16634636
[TBL] [Abstract][Full Text] [Related]
3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and forster resonance energy transfer suggest weak interactions between fibroblast growth factor receptor 3 (FGFR3) transmembrane domains in the absence of extracellular domains and ligands.
Li E; You M; Hristova K
Biochemistry; 2005 Jan; 44(1):352-60. PubMed ID: 15628877
[TBL] [Abstract][Full Text] [Related]
4. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
5. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
6. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Li E; You M; Hristova K
J Mol Biol; 2006 Feb; 356(3):600-12. PubMed ID: 16384584
[TBL] [Abstract][Full Text] [Related]
7. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
[TBL] [Abstract][Full Text] [Related]
8. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer.
Sarabipour S; Del Piccolo N; Hristova K
Acc Chem Res; 2015 Aug; 48(8):2262-9. PubMed ID: 26244699
[TBL] [Abstract][Full Text] [Related]
9. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
Khnykin D; Olsnes S
Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
[TBL] [Abstract][Full Text] [Related]
10. NMR-based approach to measure the free energy of transmembrane helix-helix interactions.
Mineev KS; Lesovoy DM; Usmanova DR; Goncharuk SA; Shulepko MA; Lyukmanova EN; Kirpichnikov MP; Bocharov EV; Arseniev AS
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):164-72. PubMed ID: 24036227
[TBL] [Abstract][Full Text] [Related]
11. Hill coefficient analysis of transmembrane helix dimerization.
Soong R; Merzlyakov M; Hristova K
J Membr Biol; 2009 Jul; 230(1):49-55. PubMed ID: 19603128
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
Sarabipour S; Hristova K
J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
[TBL] [Abstract][Full Text] [Related]
13. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
14. Terminal residue hydrophobicity modulates transmembrane helix-helix interactions.
Ng DP; Deber CM
Biochemistry; 2014 Jun; 53(23):3747-57. PubMed ID: 24857611
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic activation of receptor tyrosine kinases in mammalian membranes.
He L; Hristova K
J Mol Biol; 2008 Dec; 384(5):1130-42. PubMed ID: 18976668
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
d'Avis PY; Robertson SC; Meyer AN; Bardwell WM; Webster MK; Donoghue DJ
Cell Growth Differ; 1998 Jan; 9(1):71-8. PubMed ID: 9438390
[TBL] [Abstract][Full Text] [Related]
17. Cysteine residues are critical for chemokine receptor CXCR2 functional properties.
Limatola C; Di Bartolomeo S; Catalano M; Trettel F; Fucile S; Castellani L; Eusebi F
Exp Cell Res; 2005 Jul; 307(1):65-75. PubMed ID: 15922727
[TBL] [Abstract][Full Text] [Related]
18. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
Sarabipour S; Hristova K
Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
[TBL] [Abstract][Full Text] [Related]
19. The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues.
Peng WC; Lin X; Torres J
Protein Sci; 2009 Feb; 18(2):450-9. PubMed ID: 19165726
[TBL] [Abstract][Full Text] [Related]
20. Neutron diffraction studies of fluid bilayers with transmembrane proteins: structural consequences of the achondroplasia mutation.
Han X; Mihailescu M; Hristova K
Biophys J; 2006 Nov; 91(10):3736-47. PubMed ID: 16950849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
